The company’s exchange filing came after market hours on Wednesday, August 19.
USFDA closes Bengaluru facility inspection
Strides said the USFDA conducted a current Good Manufacturing Practices (cGMP) inspection of its Bengaluru facility from May 12 to May 20, 2026. The inspection concluded with the issuance of a Form 483 containing five observations.
The company said it submitted a comprehensive response addressing all five observations within the stipulated timeline.
Based on the company’s response and the corrective and preventive actions implemented, the USFDA classified the inspection outcome as VAI and issued the EIR, thereby concluding the inspection.
The VAI classification formally closes the inspection with no mandatory corrective actions required, according to the details provided. The cGMP inspection was conducted from May 12 to May 20, 2026, following which the facility was issued a Form 483 containing five observations.
The Bengaluru plant is Strides’ flagship manufacturing facility and produces primary finished dosage formulations, including tablets, soft and hard gelatin capsules, liquids and semi-solid drugs. The facility caters to regulated markets, including the US, with sales of around $250 million from these markets.
The Bengaluru facility serves regulated and other international markets and supports existing commercial products as well as future growth opportunities.
Q1 results
Strides Pharma Science reported a 57.5% year-on-year rise in net profit to ₹157 crore in Q1FY27, while revenue increased 13% to ₹1,265.4 crore. Growth was supported by its Ex-US markets, where revenue rose 17% to ₹587.5 crore, while US revenue increased 4% to ₹628.2 crore.EBITDA grew 5.4% year-on-year to ₹230 crore, although EBITDA margin narrowed to 18% from 19.5% a year earlier. The company said higher operating and freight costs related to the ongoing geopolitical situation impacted profitability by around ₹13.1 crore.Managing Director and Group CEO Badree Komandur said investments in Ex-US markets are beginning to deliver results, supporting Strides’ diversified growth strategy. He added that the company remains focused on cost optimisation to offset geopolitical cost pressures while pursuing sustainable and profitable growth.
During the quarter, Strides also unlocked ₹100 crore through the sale of its majority stake in Pivot Path, its captive global capability centre, while retaining a meaningful interest in the business.
Having pared some of the initial gains, shares of Strides Pharma are trading 6.2% higher on Thursday at ₹1,017.3. The stock, with this move, has extended its year-to-date advance to 11%.
Also read: Stocks To Buy: Jefferies projects 37% upside for this newly listed fintech firm
